Risk factors

Genelux (GNLX) risk factors

Item 1A of every Genelux Corp. 10-K on file, and what changed from one year to the next.

Open GNLX in Gloomberb →
  • FY2025 10-K risk factors

    83 risks, 4 new, 1 dropped, 8 reworded since the prior year. Genelux is advancing its lead immunotherapy candidate, Olvi-Vec, while managing ongoing clinical trials and capital needs.

    Filed Mar 19, 2026
  • FY2024 10-K risk factors

    80 risks. Genelux faces substantial ongoing losses and a going concern warning, with its clinical pipeline heavily dependent on its lead oncolytic vaccine candidate, Olvi-Vec.

    Filed Mar 28, 2025